To investigate the impact of the inflammatory cytokine IL-2 on antigen-expanded CD8+ T cells, we developed a novel study model, based on the combined use of mature allogeneic monocyte-derived DCs (Supplementary Figure S1) and a PC-3 prostate cancer cell line (Supplementary Figure S2A). This evidence concerns the gene IL2 and prostate cancer.